Amphastar: Baqsimi Props Up Flat Growth, But 2026 Guidance Looks Fragile [Seeking Alpha]
Amphastar Pharmaceuticals, Inc. (AMPH)
Last amphastar pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amphastar.com/investor-relations
Company Research
Source: Seeking Alpha
AMPH's revenue is propped up by BAQSIMI and PRIMATENE, while legacy generics decline and gross margins slip to 51.4%. Management's 2026 guidance for high single-digit to low double-digit growth is fragile, hinging on uncertain pipeline launches and patent cliffs. The company's transition from generics to branded/proprietary assets is slow, with pipeline assets facing high clinical and regulatory risk. carolo7/iStock via Getty Images Introduction Amphastar Pharmaceuticals ( AMPH ) is a name that I've become increasingly cautious about. While its stock was, and still is, arguably cheap, per conventional measures like P/E, I proposed in my last analysis that this was This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation f
Show less
Read more
Impact Snapshot
Event Time:
AMPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMPH alerts
High impacting Amphastar Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMPH
News
- Will FDA Approval of an In-House Teriparatide Pen Reshape Amphastar Pharmaceuticals' (AMPH) Narrative? [Yahoo! Finance]Yahoo! Finance
- 2 Russell 2000 Stocks for Long-Term Investors and 1 Facing Challenges [Yahoo! Finance]Yahoo! Finance
- Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by analysts at Barclays PLC to a "hold" rating.MarketBeat
- Amphastar Pharmaceuticals (NASDAQ:AMPH) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $30.00 price target on the stock.MarketBeat
- Amphastar Pharmaceuticals (AMPH) Stock Trades Up, Here Is Why [Yahoo! Finance]Yahoo! Finance
AMPH
Earnings
- 11/6/25 - Beat
AMPH
Sec Filings
- 12/15/25 - Form 4
- 12/11/25 - Form 144
- 12/10/25 - Form 144
- AMPH's page on the SEC website